IIRC, in some of the historical trials the bisantrene dose was too low. So that's because those trials weren't targeted to any markers? Whereas an even lower dose is expected to be effective when targeted?
Ann: Race appoints clinical & FDA regulatory strategy advisor, page-54
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.63 |
Change
0.000(0.00%) |
Mkt cap ! $276.9M | |||
| Open | High | Low | Value | Volume |
| $1.64 | $1.64 | $1.62 | $56.91K | 35.04K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4461 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 4075 | 1 |
View Market Depth
| Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
| RAC (ASX) Chart |